The review, published on 10 October 2026 and supported by the Israel Science Foundation and the National Science Foundation, synthesizes evidence across three levels of analysis: cognitive-emotional processes, neural circuitry, and temporal dynamics. At the cognitive level, the authors identify two core processes through which REM sleep may shape stress responses. The first is intrusive memory formation, the phenomenon in which distressing experiences resurface involuntarily as flashbacks or nightmares, a hallmark of posttraumatic stress disorder (PTSD). The second is threat and safety learning, the way the brain encodes cues that predict danger and cues that signal security. Both processes are strongly modulated by sleep, and REM sleep in particular appears to influence whether emotional memories are weakened, strengthened, or reorganized during the nights that follow a stressful event.

The mechanistic plausibility of these interactions rests on shared neuroanatomy. REM-associated emotional and threat-related memory processing engages limbic-prefrontal circuitry that substantially overlaps with the neural systems supporting stress responses. Regions such as the amygdala, hippocampus, and medial prefrontal cortex are central to both domains: they evaluate threat, regulate the physiological stress response, and are preferentially reactivated or modulated during REM sleep. This overlap means that changes in REM sleep architecture are not merely a byproduct of stress but could feed back into the very circuits that determine how strongly a person reacts to the next stressor. The review frames this as a bidirectional loop, with stress altering subsequent REM sleep and REM sleep, in turn, shaping later stress outcomes.

The temporal dimension is where the review makes its most distinctive contribution. Stress does not simply change REM sleep once; it perturbs it over time, and the pattern of that perturbation may carry more information than any single measurement. Animal and human studies have shown that acute stressors can produce a transient increase in REM sleep, sometimes interpreted as the brain’s attempt to process the event, while chronic or severe stress can fragment and suppress REM architecture. Conversely, the authors review evidence that REM sleep before a stressor predicts how individuals respond to it later, suggesting that pre-stress sleep is not just a passive readout of current state but an active predictor of resilience or vulnerability.

From this synthesis the authors build their resilience framework. The central claim is that an adaptive stress response may involve moderate changes in REM sleep architecture following stress exposure that resolve over time. In other words, a temporary surge or shift in REM after a difficult event is not inherently pathological; it may reflect the brain doing adaptive work. What matters is whether the system returns toward baseline. Persistent perturbation, by contrast, may signal a failure of recovery and a trajectory toward psychopathology. This reframing dissolves much of the apparent contradiction in the field: studies reporting that REM is protective may have captured the transient, adaptive phase, while studies reporting that REM is harmful may have captured the chronic, unresolved phase, or compared groups whose trajectories differed in ways a single-night measurement could not detect.

To demonstrate the framework’s explanatory power, the review walks through four illustrative cases showing how seemingly conflicting findings can be reconciled when the timing and trajectory of REM measurement are taken into account. A study that finds elevated REM after trauma is associated with worse outcomes, for example, need not contradict a study finding that REM promotes emotional recovery, if the first measured REM days after a severe stressor in individuals whose perturbation failed to resolve while the second measured the acute adaptive response to a milder event. The framework also accommodates state-like effects, which are short-term and reversible, and trait-like processes, which reflect stable individual differences in how the REM system responds to challenge. Both types of influence can coexist, and disentangling them requires longitudinal designs rather than cross-sectional snapshots.

The clinical implications are most evident for PTSD, a disorder in which disturbed REM sleep, nightmares, and intrusive memories are tightly interwoven. If the trajectory of REM perturbation and recovery is the critical variable, then monitoring REM architecture over days and weeks after trauma exposure could help identify which individuals are on a maladaptive course before full symptoms emerge. Interventions targeting sleep, whether pharmacological or behavioral, might be timed to support the recovery phase rather than simply to normalize REM levels. The framework also suggests that treatments should be evaluated not by whether they change REM on any single night but by whether they accelerate the return of REM architecture toward its pre-stress pattern.

The authors are careful to note that the review is a synthesis of existing evidence rather than a report of new experimental data, and that many of its claims rest on correlational findings that call for stronger causal tests. They explicitly outline future longitudinal research designs that could improve understanding of bidirectional REM-stress interactions, including studies that track individuals repeatedly across the full arc of stress exposure and recovery. Such designs would allow researchers to distinguish within-person change from between-person difference, the distinction that lies at the heart of the resilience framework. They would also make it possible to test whether the trajectory of REM recovery predicts later stress outcomes prospectively, rather than being inferred retrospectively.

For the broader field of sleep and stress research, the framework offers a practical shift in methodology: measure trajectories, not points. For the public, it carries a more accessible message. A rough night or two of vivid, emotionally charged dreams after a stressful experience may not be a sign that sleep is failing; it may be part of how the brain metabolizes the event. The concern arises when that perturbation does not settle. By recasting REM sleep from a fixed good-or-bad actor into a dynamic system whose recovery curve carries the diagnostic signal, Maimon, Lerner, and Admon provide a unifying lens for a literature that has often seemed to talk past itself, and a concrete agenda for turning sleep measurement into a tool for predicting and protecting mental health after stress.

Subject of Research: Bidirectional interactions between REM sleep architecture and stress responses, framed through a resilience-based model of REM perturbation and recovery

Article Title: Bidirectional interactions between REM sleep and stress responses through the lens of the resilience framework

Article References: Maimon, E., Lerner, I., & Admon, R. (2026). Bidirectional interactions between REM sleep and stress responses through the lens of the resilience framework. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04524-2

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04524-2

Keywords: REM sleep, stress responses, resilience, PTSD, emotional memory, threat learning, limbic-prefrontal circuitry, sleep architecture, intrusive memories, longitudinal research, Translational Psychiatry, mental health

Sleep-disordered breathing, or SDB, encompasses a spectrum of conditions in which airflow during sleep is partially or completely obstructed. At the milder end lies habitual snoring, where the soft tissues of the upper airway vibrate noisily but breathing remains largely intact. At the severe end sits obstructive sleep apnea, or OSA, in which the airway collapses repeatedly, causing pauses in breathing, drops in blood oxygen, and abrupt micro-awakenings that fragment sleep into shards. Children with OSA often appear exhausted during the day, struggle with attention and learning, and in some cases develop behavioral problems that mimic attention-deficit hyperactivity disorder. The condition is far from rare, and its prevalence is believed to be rising alongside childhood obesity.

Allergic rhinitis, meanwhile, is one of the most common chronic conditions of childhood. It inflames the nasal mucosa, produces congestion and postnasal drip, and has long been associated with poor sleep quality in both children and adults. Previous studies have established that children with allergic rhinitis are more likely to snore and more likely to be diagnosed with sleep-disordered breathing. What remained murky was precisely how the allergy affects the architecture of sleep itself—particularly the delicate machinery of arousals, the brief awakenings that the sleeping brain deploys in response to internal disturbances. The new research, led by Tzu-Yuan Kang and Wan-Yu Lai of China Medical University Hospital in Taichung, set out to illuminate that relationship with the help of polysomnography, the gold-standard technique for measuring sleep.

Polysomnography is an elaborate overnight recording in which electrodes track brain waves, eye movements, muscle tone, heart rhythm, airflow, and blood oxygen. From these signals, sleep technicians can identify every respiratory event, every limb movement, and every arousal, and can compute indices that quantify how frequently each occurs per hour of sleep. The respiratory arousal index, or RAI, counts the awakenings triggered specifically by breathing disturbances, while the spontaneous arousal index captures awakenings with no identifiable trigger, and the periodic limb movement arousal index tallies those caused by involuntary leg jerks. Together, these measures offer a granular portrait of how fragmented a child’s sleep truly is.

The Taiwanese team conducted a retrospective analysis of polysomnography data collected between 2009 and 2020 at a tertiary hospital, focusing on children under twelve years of age who had been evaluated for sleep-disordered breathing. The participants were sorted into four groups according to their polysomnographic findings and clinical diagnoses, distinguishing children with obstructive sleep apnea from those with simple snoring, and accounting for whether allergic rhinitis was present. In total, 643 children were included in the analysis. The researchers then applied multivariable regression models to tease apart the independent contributions of allergy, obesity, age, sex, asthma, and other comorbidities to the various arousal indices.

The results were unambiguous. Children with obstructive sleep apnea who also suffered from allergic rhinitis exhibited significantly more respiratory events and a significantly higher respiratory arousal index than their counterparts without the allergy, with both differences reaching statistical significance at P less than 0.001. In other words, the combination of a blocked, inflamed nose and an already compromised airway produced measurably more fragmented sleep than either condition alone. This finding aligns with the mechanistic intuition that nasal inflammation narrows the upper airway, increases negative pressure during inspiration, and thereby lowers the threshold at which each breathing effort triggers a cortical awakening.

But the study also produced a genuinely surprising result. Using multivariable negative binomial regression—a statistical approach suited to count data such as arousal counts—the team found that allergic rhinitis was independently associated with a lower periodic limb movement arousal rate, with an adjusted incidence rate ratio of 0.393 and a 95 percent confidence interval spanning 0.183 to 0.848. This association held even after the researchers adjusted for comorbid asthma and OSA status. The finding, reported at P equal to 0.017, suggests that allergic rhinitis does not simply amplify every form of sleep disruption; rather, it appears to reshape the pattern of arousals in a selective way, boosting respiratory-driven awakenings while somehow dampening those driven by limb movements. The authors describe this as the first evidence of a significant link between allergic rhinitis and impaired arousal regulation in pediatric sleep-disordered breathing.

The regression analysis also mapped the broader landscape of factors that drive respiratory arousals in children. Older age was associated with a modestly lower respiratory arousal rate, with an adjusted incidence rate ratio of 0.914 at P equal to 0.011, hinting that the airways of older children may be more resilient to collapse. Male sex emerged as a risk factor, with a ratio of 1.643 at P equal to 0.006, consistent with the well-documented male predominance in sleep apnea. Higher body mass index carried a ratio of 1.048 per unit at P equal to 0.018, underscoring the metabolic dimension of the disease. Most dramatically, the presence of obstructive sleep apnea itself carried a ratio of 12.382 at P less than 0.0001, confirming that a formal apnea diagnosis is by far the strongest predictor of respiratory-driven sleep fragmentation. Enuresis, or bedwetting, was also independently associated with higher respiratory arousal rates, with a ratio of 2.065 at P equal to 0.029—a connection that may reflect the way sleep fragmentation disrupts the hormonal regulation of nighttime urine production.

The clinical implications of the study are considerable. The authors argue that their findings underscore the necessity of screening for sleep disturbances in children with allergic rhinitis, a population that pediatricians frequently encounter but whose sleep problems may go unexamined. A child brought in for chronic sneezing and congestion may, in fact, be harboring significant sleep fragmentation that affects cognition, mood, growth, and cardiovascular health. Conversely, the results suggest that managing comorbid allergic rhinitis is a critical component of pediatric sleep disorder therapy. For a child undergoing evaluation or treatment for snoring or obstructive sleep apnea, leaving the underlying allergy untreated may undermine the effectiveness of interventions ranging from nasal surgery to adenotonsillectomy, the most common surgical treatment for pediatric OSA.

The study is not without limitations inherent to its design. As a retrospective, single-center analysis, it relied on children who had already been referred for sleep evaluation, which may limit generalizability to the broader population of allergic children who snore. The authors also note that the manuscript was prepared with assistance from the generative AI tool Gemini to improve grammatical accuracy and readability, with the authors reviewing and editing the content and taking full responsibility for it. The research was supported by the Holistic Health care Foundation of China Medical University Hospital, and the ethics review board of the hospital approved the study with a waiver of informed consent given its retrospective nature. Even so, the work opens a compelling new window onto the physiology of childhood sleep. It suggests that the brain’s arousal system, far from being a passive victim of airway obstruction, is dynamically modulated by allergic inflammation—and that the humble stuffy nose may hold more power over a child’s sleeping brain than anyone had previously measured.

Subject of Research: The association between allergic rhinitis and polysomnographic arousal indices in children with sleep-disordered breathing

Article Title: Association of allergic rhinitis with polysomnographic arousal indices in children with sleep-disordered breathing

Article References: Kang, T.-Y., Wei, C.-C., Hang, L.-W., Li, Y.-H., Yen, H.-R., Wang, J.-Y., Lin, C.-H., & Lai, W.-Y. (2026). Association of allergic rhinitis with polysomnographic arousal indices in children with sleep-disordered breathing. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07684-8

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07684-8

Keywords: allergic rhinitis, sleep-disordered breathing, obstructive sleep apnea, polysomnography, arousal index, pediatrics, snoring, respiratory arousal index, sleep architecture, asthma, enuresis, children's sleep

The findings, published in Translational Psychiatry, come from a clinical trial registered as NCT00088699 and conducted under the Intramural Research Program of the National Institutes of Health. Treatment-resistant depression, typically defined as depression that fails to respond adequately to two or more adequate antidepressant trials, affects a substantial minority of the millions of people living with major depressive disorder worldwide. For these patients, insomnia and anxiety are not incidental companions but core burdens that shape daily functioning, suicide risk and quality of life. Understanding whether ketamine relieves these burdens together or separately is therefore far more than an academic exercise; it determines how clinicians should monitor, counsel and follow up with patients in the critical first day after infusion.

The study’s design was straightforward but rigorous. Each participant was assessed at baseline, immediately before receiving the infusion, and again twenty-four hours afterward. Depression severity was quantified with the Montgomery–Åsberg Depression Rating Scale, a clinician-administered instrument widely regarded as sensitive to rapid change. Anxiety was measured with the Hamilton Anxiety Rating Scale, and insomnia was captured using the insomnia items embedded in the Hamilton Depression Rating Scale. To analyze the data, the researchers employed linear mixed-effects models, a statistical framework that can account for repeated measurements within the same individual while estimating the average pre-to-post change across the group. The results were unambiguous: depression scores fell by an estimated 11.72 points on the MADRS, anxiety scores dropped by 7.87 points on the HAM-A, and insomnia scores declined by 0.89 points, with all three changes reaching statistical significance at P less than 0.001.

Those headline numbers confirm what a growing body of literature has suggested since the early 2000s, when researchers first reported that a subanesthetic dose of ketamine could lift depressive symptoms within hours in patients who had exhausted conventional options. Ketamine acts primarily as an antagonist of the N-methyl-D-aspartate receptor, a glutamate-gated ion channel, and its rapid antidepressant effects are thought to be mediated downstream through activation of AMPA receptors, stimulation of brain-derived neurotrophic factor signaling, and the restoration of synaptic connections eroded by chronic stress. The metabolite (2R,6R)-hydroxynorketamine has also been implicated in the antidepressant response, a discovery that has fueled an entire pipeline of ketamine-derived therapeutics now in clinical development.

But the real novelty of the new study lies in its dissection of how the three symptom domains interact. At baseline, before any drug was given, insomnia severity showed a moderate correlation with anxiety severity, with a Spearman rank correlation coefficient of 0.36, and anxiety correlated with depression with a Pearson correlation coefficient of 0.39. After ketamine, the association between anxiety and depression actually strengthened, rising to a Pearson correlation of 0.57, while the insomnia-anxiety link held steady at a Spearman coefficient of 0.36. Most tellingly, when the researchers computed change scores for each domain and correlated them, changes in anxiety were strongly associated with changes in depression, with a Spearman coefficient of 0.61, whereas changes in insomnia were not significantly associated with changes in either of the other two domains.

This dissociation carries real clinical weight. If insomnia improvement were simply a downstream consequence of mood lifting, one would expect patients whose depression improved most to also sleep most dramatically better. The data say otherwise. Instead, the study found that the single best predictor of how much a patient’s insomnia improved was how severe that insomnia was at baseline: greater baseline insomnia severity was associated with larger absolute reductions in insomnia scores. In other words, ketamine appears to act on sleep complaints in proportion to how disturbed sleep was to begin with, rather than as a ripple effect of the drug’s antidepressant action. This pattern hints at partially separable neurobiological mechanisms, perhaps involving ketamine’s effects on arousal circuitry, glutamatergic signaling in sleep-regulating regions, or the drug’s known sedative and psychotomimetic properties during the acute infusion period.

Supporting this interpretation, exploratory polysomnography analyses conducted in a subset of participants suggested objective sleep changes in the twenty-four hours after infusion: total sleep time increased, slow-wave sleep, the deep restorative stage most associated with synaptic homeostasis, increased, sleep efficiency improved, and sleep latency, the time it takes to fall asleep, shortened. Polysomnography, the gold standard for sleep measurement, records brain waves, eye movements, muscle tone and breathing overnight, providing an objective counterpoint to questionnaire-based insomnia ratings. The concordance between subjective insomnia improvement and objective sleep architecture changes, while exploratory in this dataset, strengthens the case that ketamine genuinely reshapes sleep physiology rather than merely altering how patients report their nights.

The research team, which included investigators from the NIMH’s Experimental Therapeutics and Pathophysiology Branch, Jena University Hospital, Philipps University of Marburg, the National Institute on Alcohol Abuse and Alcoholism, the University of Wisconsin-Madison and the University of British Columbia, went one step further by attempting to classify which patients would experience insomnia improvement. Using linear discriminant analysis and logistic regression as exploratory tools, they sought statistical signatures that might separate improvers from non-improvers. Such classification approaches, if validated in larger samples, could eventually help clinicians identify before an infusion which patients are likely to gain sleep benefits, allowing targeted adjunctive treatments, such as cognitive behavioral therapy for insomnia, for those less likely to respond on the sleep front.

The study is not without limitations, and the authors are careful to frame the insomnia findings appropriately. The insomnia measure was derived from items within the Hamilton Depression Rating Scale rather than a dedicated insomnia instrument, which may limit sensitivity to the full breadth of sleep complaints. The twenty-four-hour window captures only the earliest phase of ketamine’s action, and the drug’s antidepressant effects typically wane over days to two weeks, raising open questions about whether the dissociation between sleep and mood trajectories persists or collapses over longer follow-up. The sample of seventy-one patients, while respectable for an intramural trial of a hard-to-treat population, limits statistical power for subgroup analyses, and the polysomnography component was explicitly exploratory. The open-access paper, published on 6 October 2026 with the DOI 10.1038/s41398-026-04443-2, also notes that the version shared early is subject to further editorial edits before the final Version of Record.

Even with those caveats, the implications are immediate. Clinicians administering ketamine for treatment-resistant depression should not assume that a patient whose mood and anxiety improve will necessarily report better sleep, nor that a poor sleep response signals treatment failure on the mood front. The two domains deserve separate monitoring, and patients can be counseled that sleep improvements, when they occur, may scale with the severity of their pre-existing insomnia rather than with the depth of their mood response. For researchers, the study adds to a shifting view of ketamine not as a single blunt instrument but as a pharmacological scalpel whose blades cut along partly independent neural pathways, and it sets the stage for mechanistic work aimed at understanding why the brain’s sleep machinery responds to this anesthetic-turned-antidepressant on a schedule of its own.

Subject of Research: Short-term effects of ketamine on depression, anxiety and insomnia symptoms in treatment-resistant depression

Article Title: Insomnia and anxiety exhibit distinct short-term associations following ketamine in treatment-resistant depression

Article References: Hejazi, N. S., Kheirkhah, M., Chholak, R., Riedner, B., Jamalabadi, H., Walter, M., Hofmann, S. G., Duncan, W., Jr, Goldman, D., & Zarate, C. A., Jr (2026). Insomnia and anxiety exhibit distinct short-term associations following ketamine in treatment-resistant depression. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04443-2

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04443-2

Keywords: ketamine, treatment-resistant depression, insomnia, anxiety, depression, polysomnography, NMDA receptor, Translational Psychiatry, sleep architecture, MADRS, HAM-A, rapid-acting antidepressants

The commentary accompanies a large epidemiological analysis drawn from TURKAPNE, a nationwide Turkish sleep apnea cohort, which found that diabetes mellitus is associated with both an increased prevalence and an increased severity of COMISA. That finding matters because COMISA is not a rare curiosity. Studies of sleep clinic populations and community cohorts suggest that a substantial share of patients diagnosed with obstructive sleep apnea also report chronic insomnia symptoms, and vice versa, yet the overlap has historically been under-recognized. Patients with COMISA often fall through diagnostic cracks: their insomnia complaint may mask the apnea during a routine visit, or the apnea diagnosis may lead clinicians to dismiss the insomnia as secondary, leaving the underlying sleep fragmentation untreated.

Part of what makes COMISA biologically plausible as a driver of metabolic disease is the distinct sleep architecture it produces. Research comparing patients with COMISA against those with obstructive sleep apnea alone or insomnia alone has shown that the combined disorder is associated with a unique pattern of sleep disruption, blending the repetitive upper airway collapses and oxygen desaturations of apnea with the prolonged sleep-onset difficulties and nocturnal awakenings characteristic of insomnia. In laboratory studies, acute intermittent hypoxia, the hallmark physiological insult of sleep apnea, has been shown to impair glucose metabolism even in awake, healthy volunteers, suggesting a direct mechanistic pathway from oxygen fluctuation to insulin resistance.

The insomnia component adds its own metabolic burden. A systematic review and meta-analysis focusing on insomnia disorder characterized by objectively short sleep duration found associations with hypertension, diabetes, and elevated body mass index. In other words, the subset of insomnia patients whose bodies cannot compensate for their sleep loss with longer time in bed appears to carry measurable cardiometabolic risk. When that short, fragmented sleep is layered on top of the cyclical hypoxemia of sleep apnea, the two insults may act synergistically on the sympathetic nervous system, the hypothalamic-pituitary-adrenal axis, and inflammatory pathways, all of which are central to glucose homeostasis.

Cardiovascular data reinforce the concern. An analysis of a large sleep registry found that type 2 diabetic patients with co-morbid insomnia and sleep apnea faced elevated cardiovascular risk compared with diabetic patients who had neither or only one of the two sleep disorders. Separately, work on the so-called hypoxic burden, a quantitative measure of the oxygen desaturation load carried during sleep, has shown that this metric predicts cardiovascular disease-related mortality better than the traditional apnea-hypopnea index in large community cohorts such as the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Sankari’s own longitudinal research on nocturnal heart rate variability, measured through R-R interval changes in a community-based cohort, has similarly pointed to autonomic dysregulation during sleep as a harbinger of adverse cardiovascular outcomes.

What the TURKAPNE findings add is epidemiological weight to the idea that the arrow may point in both directions. Diabetes is associated with more prevalent and more severe COMISA, but the mechanistic literature suggests COMISA may also worsen glycemic control, creating a potential feedback loop. Hyperglycemia can promote nocturia, neuropathic pain, and restless discomfort that fragment sleep, while fragmented, hypoxic sleep promotes insulin resistance, appetite dysregulation through altered leptin and ghrelin signaling, and weight gain, which in turn worsens both apnea severity and metabolic control. Breaking this loop, the commentary argues, requires treating the two sleep disorders together rather than sequentially.

Treatment evidence is beginning to catch up with the biology. The most striking recent development comes from trials of tirzepatide, a dual incretin agonist originally developed for diabetes and obesity, which demonstrated significant reductions in the apnea-hypopnea index in patients with obstructive sleep apnea and obesity. Meta-analytic work on weight reduction more broadly confirms that even modest weight loss produces meaningful drops in apnea severity. For patients with COMISA and type 2 diabetes, these agents occupy a uniquely attractive position, because they simultaneously target the metabolic disease, the body weight that drives airway collapse, and potentially the sleep-disordered breathing that feeds back into glycemic instability. Whether they also ameliorate the insomnia component of COMISA remains an open question that researchers are only beginning to explore.

The pharmacological picture is complicated by safety concerns on the insomnia side. Longitudinal primary care data have linked prescriptions of hypnotics and anxiolytics with increased mortality, particularly in multimorbid patients, a category that describes many older adults with type 2 diabetes and coexisting sleep disorders. This makes non-pharmacological approaches, above all cognitive behavioral therapy for insomnia, the preferred first-line option for the insomnia component, while positive airway pressure therapy remains the cornerstone of apnea treatment. The challenge, as the commentary emphasizes, is that adherence to positive airway pressure is notoriously poor among patients with comorbid insomnia, who may find the mask and airflow intolerable when they already struggle to fall asleep. Integrated treatment pathways that address both disorders from the outset, rather than treating apnea first and hoping insomnia resolves, may improve adherence and outcomes for both.

Screening represents another frontier. Obstructive sleep apnea in women, particularly around reproductive aging and menopause, is frequently missed because presenting complaints differ from the classic male phenotype of loud snoring and witnessed apneas, and insomnia symptoms can further obscure the picture. Sankari and colleagues have highlighted these screening challenges in recent work, and the same logic applies to diabetic patients of both sexes: a patient who reports difficulty falling or staying asleep should prompt clinicians to consider whether sleep-disordered breathing is hiding underneath, and a patient prescribed continuous positive airway pressure who remains fatigued should be evaluated for persistent insomnia. Simple validated screening instruments for both conditions could be deployed in endocrinology and primary care clinics at minimal cost.

The commentary’s central message is ultimately one of reframing. Coexistence is not the right word for what happens when diabetes, insomnia, and sleep apnea converge in a single patient; the evidence points toward genuine pathophysiological entanglement, with each condition amplifying the others through hypoxic stress, autonomic activation, inflammatory signaling, and behavioral pathways such as sedentary fatigue and disordered eating. Large prospective cohorts that track sleep architecture, hypoxic burden, and glycemic outcomes simultaneously will be needed to establish causality and to determine whether treating COMISA aggressively improves diabetes complications and cardiovascular survival. Until then, the practical takeaway for clinicians is clear: in a patient with type 2 diabetes who sleeps badly, neither the insomnia nor the apnea should be treated as background noise, because together they may be quietly driving the disease that brought the patient to the clinic in the first place.

Subject of Research: The bidirectional relationship between type 2 diabetes and comorbid insomnia and sleep apnea (COMISA)

Article Title: Beyond coexistence: attempting to unlock the diabetes–COMISA Link

Article References: Sankari, A. (2026). Beyond coexistence: attempting to unlock the diabetes–COMISA link. Journal of Clinical Sleep Medicine, 22(1), Article 125. https://doi.org/10.1007/s44470-026-00135-2

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00135-2

Keywords: COMISA, type 2 diabetes, obstructive sleep apnea, insomnia, sleep medicine, intermittent hypoxia, glucose metabolism, cardiovascular risk, TURKAPNE cohort, tirzepatide, cognitive behavioral therapy for insomnia, sleep architecture

The study tapped the Northern Finland Birth Cohort 1986, one of the world’s longest-running population-based longitudinal studies, which has followed thousands of individuals since before birth. When participants reached 33 to 35 years of age, they were asked to wear an Oura Ring, a commercially available smart ring, for two weeks. To ensure the data were robust, the researchers only included participants who provided at least one weekday and one weekend day with no less than fifteen hours of wear time. That filtering step left 1,290 participants with valid recordings, a remarkably large sample for research involving continuous physiological monitoring.

During those two weeks, the ring captured an unusually rich set of digital metrics. It recorded sleep architecture, meaning the distribution of sleep stages across the night, including rapid eye movement (REM) sleep, deep sleep, and light sleep. It measured nocturnal heart rate using photoplethysmography, an optical technique that tracks blood volume pulses beneath the skin. It derived heart rate variability, indexed by the root mean square of successive differences between normal heartbeats, a statistic known as RMSSD that reflects the fine-tuned activity of the autonomic nervous system. And it logged minute-by-minute movement intensity throughout the day, providing an objective picture of physical activity levels.

Mental health symptoms were assessed with two well-validated screening instruments. The Generalized Anxiety Disorder 7-item scale, or GAD-7, quantified anxiety symptoms, allowing participants to be grouped into no, mild, and moderate-to-severe symptom categories. The Hopkins Symptom Checklist-25, or HSCL-25, captured a broader blend of depression and anxiety symptoms, dividing participants into those with and without clinically relevant symptom burden. The researchers then compared the wearable-derived metrics across these groups using analysis of covariance, a statistical technique that controls for potential confounding variables, followed by Tukey’s post hoc test to pinpoint which group differences were statistically meaningful.

The results were striking in their consistency. Participants with moderate-to-severe anxiety on the GAD-7, and those flagged by the HSCL-25 as having depression and anxiety symptoms, spent a lower percentage of the night in REM sleep and deep sleep, and a higher percentage in light sleep, compared with participants who reported no depression or anxiety. REM sleep is the stage most closely associated with emotional memory processing and mood regulation, while deep sleep supports physical restoration and cognitive function. A shift away from these restorative stages toward lighter, more fragmented sleep is a well-documented feature of mood and anxiety disorders, but it had rarely been captured so cleanly in a free-living population using an unobtrusive consumer device.

The physiological differences extended beyond sleep staging. The symptomatic groups showed higher nocturnal heart rates and lower RMSSD during sleep, a combination that points to sustained sympathetic arousal, the fight-or-flight branch of the autonomic nervous system remaining more active than usual even during rest. Elevated resting heart rate and suppressed heart rate variability are classic correlates of chronic stress and have been linked in prior research to cardiovascular risk, making their presence in young adults with mental health symptoms particularly noteworthy. In parallel, the same groups recorded lower levels of physical activity during the day, consistent with the fatigue, anhedonia, and behavioral withdrawal that often accompany depression and anxiety.

Notably, the picture was less clear-cut for people with mild anxiety. The differences between the mild anxiety group and both the symptom-free and moderate-to-severe groups were overall less apparent on average, suggesting that the wearable metrics scale with symptom severity rather than merely detecting the presence of any symptoms at all. This dose-response-like pattern strengthens the argument that the ring’s data carry genuine signal about mental state, rather than simply flagging anyone who differs from the population average. It also hints at a potential role for such devices in tracking symptom trajectories over time, since worsening physiology might accompany worsening symptoms.

The researchers describe these wearable-derived measures as digital biomarkers, objective physiological and behavioral signals that can be collected continuously and passively in everyday life. The concept of digital phenotyping, using data from personal devices to characterize health states, has gained momentum as smartphones and wearables have become ubiquitous. What distinguishes this study is its population-based design and its use of a consumer-grade device rather than research-grade laboratory equipment. Polysomnography, the gold standard for sleep measurement, requires an overnight clinic stay with electrodes glued to the scalp and chest, an experience so intrusive that a single night’s recording may not represent typical sleep. A ring, by contrast, collects weeks of data in the participant’s own bed.

The implications reach into clinical practice and public health alike. Depression and anxiety are among the most common mental health conditions worldwide, yet they are frequently underdiagnosed, and treatment monitoring typically relies on periodic self-report questionnaires that are vulnerable to recall bias and stigma. If wearable metrics can complement these tools, clinicians might one day spot early warning signs between appointments, tailor interventions to individual physiological profiles, and evaluate treatment response with far greater temporal resolution. The study’s authors suggest that consumer wearables may be a promising tool for enhancing symptom tracking and informing personalized care strategies, though they stop short of claiming diagnostic capability.

Important caveats remain. The study was cross-sectional, capturing a snapshot in time, so it cannot determine whether the physiological differences cause the symptoms, result from them, or arise from shared underlying factors. The cohort, born in northern Finland in 1986, is predominantly young and Finnish, and generalization to other ages and populations will require further study. Screening questionnaires are not clinical diagnoses, and the effect sizes, while statistically significant, describe group averages rather than individual predictions. Still, the scale and consistency of the findings mark a milestone for the field. As wearables spread to hundreds of millions of wrists and fingers, the quiet data they gather each night may prove to be one of the most valuable untapped resources in mental health research, turning an ordinary consumer gadget into a sentinel for the mind.

Subject of Research: Digital biomarkers of depression and anxiety severity measured with a consumer wearable ring

Article Title: Severity of depression and anxiety symptoms is reflected in physiological and behavioral metrics collected from a consumer-grade wearable ring

Article References: Azadifar, S., Sameh, A., Nauha, L., Kärmeniemi, M., Niemelä, M., & Farrahi, V. (2026). Severity of depression and anxiety symptoms is reflected in physiological and behavioral metrics collected from a consumer-grade wearable ring. BMC Medicine, 24(1), Article 532. https://doi.org/10.1186/s12916-026-05276-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05276-y

Keywords: wearable technology, digital biomarkers, depression, anxiety, Oura ring, sleep architecture, heart rate variability, mental health, digital phenotyping, Northern Finland Birth Cohort, BMC Medicine, population health

The commentary, authored by Sasikanth Gorantla of the Emory University School of Medicine, Katyayini Aribindi of the University of California, Davis, and Vishesh K. Kapur of the University of Washington School of Medicine, responds to a population-based cohort study showing that sleep homeostasis is impaired across the full spectrum of obstructive sleep apnea severity. That finding, the authors contend, elevates sleep homeostasis from an abstract concept of sleep science to a measurable clinical signal, one that could reshape how researchers and physicians evaluate the burden of the disease and the success of its treatment.

Sleep homeostasis is one half of the classic two-process model of sleep regulation, first articulated by Alexander Borbély in 1982. The model holds that sleep timing and depth are governed by the interaction of a circadian process, which rhythms sleep and wakefulness across the day, and a homeostatic process, an hourglass-like accumulation of sleep need that builds during waking hours and dissipates during sleep. The electrophysiological signature of this homeostatic process is most visible in the electroencephalogram as slow-wave activity, the low-frequency delta power that dominates deep non-REM sleep and declines progressively across a night of rest.

Decades of research in animal models and humans have established that this slow-wave signature is not merely a byproduct of sleep but a reflection of genuine neurophysiological work. Studies of freely behaving rats by Vyazovskiy, Cirelli and Tononi demonstrated that the electrophysiological correlates of sleep homeostasis are tightly linked to the duration of prior wakefulness. The influential synaptic homeostasis hypothesis proposed by Tononi and Cirelli goes further, suggesting that slow-wave activity during sleep actively downscales synapses strengthened during wakefulness, protecting neural circuits from saturation and preserving the brain’s capacity for plasticity, learning and memory consolidation.

Against this backdrop, the notion that obstructive sleep apnea disrupts sleep homeostasis takes on considerable significance. The disorder fragments sleep with repeated collapses of the upper airway, each accompanied by oxygen desaturation and an arousal that shatters the continuity of deep sleep. But the commentary emphasizes that the damage is not simply a matter of sleep loss. The recurring hypoxic and ventilatory stresses of apnea appear to interfere with the very mechanisms that generate and dissipate homeostatic sleep pressure, leaving patients with a brain that has neither slept deeply enough nor recovered adequately, even after nights that seem, on paper, to contain sufficient hours of sleep.

Recent landmark studies have already shown why conventional indices fall short. The hypoxic burden of sleep apnea, a measure of the severity of oxygen deprivation rather than the frequency of breathing events, predicted cardiovascular disease-related mortality in large cohorts including the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Similarly, ventilatory burden, which quantifies the respiratory effort expended against a collapsed airway, proved predictive of cardiovascular and all-cause mortality in work published in the American Journal of Respiratory and Critical Care Medicine. These alternative measures capture physiological stress that the apnea-hypopnea index misses, and sleep homeostasis, the commentary argues, belongs squarely in this emerging family of clinically meaningful severity markers.

The implications for treatment evaluation are particularly striking. Continuous positive airway pressure, the standard therapy for obstructive sleep apnea, has produced famously mixed results in trials of neurocognitive outcomes, including the large APPLES study, and real-world registry data on its effect on sleepiness reveal variable benefit. The commentary notes that sleep architecture impairment and cognitive performance vary substantially across apnea phenotypes, and that conventional polysomnographic outcomes may be too blunt to detect which patients genuinely recover restorative sleep under therapy. Quantifying slow-wave activity and other markers of homeostatic sleep regulation could provide a sensitive readout of whether treatment is actually restoring the brain’s recovery processes, not merely eliminating respiratory events.

The commentary also situates sleep homeostasis within a broader neurophysiological context. Recent imaging work in humans has revealed coupled electrophysiological, hemodynamic and cerebrospinal fluid oscillations during sleep, suggesting that slow-wave activity coordinates a large-scale clearance and restoration program in the brain. Pharmacological studies complicate the picture further: caffeine reduces low-frequency delta activity in the sleep EEG, benzodiazepines such as temazepam alter slow waves in ways that do not necessarily restore normal homeostatic function, and antidepressants including fluoxetine and trazodone reshape sleep architecture with distinct effects on slow-wave activity. Any clinical use of sleep homeostasis as an outcome measure will therefore need to account for these pharmacological and physiological confounders.

For the field of sleep medicine, the commentary’s central message is one of expansion rather than replacement. The apnea-hypopnea index remains useful for diagnosis and disease classification, but it was never designed to capture the neurophysiological consequences of the disorder. Sleep homeostasis, measurable through standard EEG recordings and increasingly through high-density and quantitative EEG techniques, offers a patient-centered, mechanism-based outcome that aligns with what patients and clinicians ultimately care about: whether the brain is recovering night after night. If validated in prospective trials, this measure could help stratify patients, personalize therapy and provide a more faithful endpoint for the next generation of apnea treatments.

The work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. As sleep researchers continue to refine how obstructive sleep apnea is defined and staged, the humble delta wave, once an academic curiosity of sleep physiology, may prove to be one of the most informative signals a clinician can read from a sleeping patient’s brain, a direct measure of the homeostatic machinery that obstructive sleep apnea quietly wears down.

Subject of Research: Sleep homeostasis as a neurophysiological outcome measure in obstructive sleep apnea

Article Title: Sleep homeostasis in OSA: a complementary neurophysiological outcome measure

Article References: Gorantla, S., Aribindi, K., & Kapur, V. K. (2026). Sleep homeostasis in OSA: a complementary neurophysiological outcome measure. Journal of Clinical Sleep Medicine, 22(1), Article 157. https://doi.org/10.1007/s44470-026-00174-9

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00174-9

Keywords: obstructive sleep apnea, sleep homeostasis, slow-wave activity, two-process model, EEG delta power, apnea-hypopnea index, hypoxic burden, ventilatory burden, CPAP treatment, synaptic homeostasis hypothesis, sleep architecture, cognitive performance